Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zagociguat in MELAS (Open-label Extension)
NCT06961344Phase 2Terminated
- Sponsor
- Tisento Therapeutics
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of zagociguat in Mitochondrial encephalomyopathy (ME), sponsored by Tisento Therapeutics. Started Aug 2025; status: terminated.
02
Drugs
zagociguat
03
Conditions
Mitochondrial encephalomyopathy (ME)
Beyond the preview
Go deeper on NCT06961344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961344.